Sorry, you need to enable JavaScript to visit this website.
Skip to main content

CURRENT TREATMENT

The KDIGO guidelines outline the current therapeutic targets for patients with IgA nephropathy (IgAN), but the majority of patients do not reach those targets1

In IgAN, the KDIGO guidelines define proteinuria targets:1

Full remission iconPartial remission icon

The guideline recommends initial treatment with long-term renin-angiotensin-aldosterone (RAA) system inhibition, angiotensin converting enzyme inhibitor (ACEi) or angiotensin II-receptor blocker (ARB). If the initial treatment is unsuccessful and the patient remains at a high risk of progression, treatment with glucocorticoids may be considered.1

Discover KDIGO treatment recommendations for IgAN

CURRENT TREATMENTS FOR IgAN

TWO PATHWAYS CONTRIBUTE TO DISEASE PROGRESSION IN IgAN

FIND OUT MORE
IgA nephropathy unmet need icon

63% of patients (N=96) DO NOT

reach the KDIGO recommended target 
with treatment4*

There is a high clinical unmet need for disease course modifying treatments that preserve kidney function for patients with IgAN5–8

In glomerular disease, target proteinuria and aim for remission

EXPLORE PROTEINURIA